Latest News
Scotland’s NHS to fund Ipsen cancer diarrhoea drug
Decision welcomed as step forward for patients
Genentech’s Rituxan approved for rare skin disease
The FDA has approved Genentech’s Rituxan (rituximab) for use in adults with moderate-to-severe pemphigus vulgaris (PV), making it the first treatment for the condition in more than 60 years.
More news
Roche’s Perjeta combo approved in Europe for early breast cancer
The European Commission (EC) has approved Roche’s Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and chemotherapy for post-surgery (adjuvant) treatment of adult patients with HER2-positive early breast cancer (eBC) at high risk of recurrence.
NICE recommends Pfizer’s Xalkori in rare lung cancer
NICE has issued a Final Appraisal Determination that recommends the use of Pfizer’s Xalkori (crizotinib) in England under the Cancer Drugs Fund (CDF) for patients with ROS1-positive advanced non-small cell lung cancer (NSCLC).
FDA approves oral treatment for ulcerative colitis
Pfizer’s janus kinase (JAK) inhibitor drug Xeljanz (tofacitinib) has received expanded approval from the FDA for adults with moderately-to-severely-active ulcerative colitis.
FDA approves UCB’s Cimzia in plaque psoriasis
The US FDA has approved a label extension for UCB’s Cimzia (certolizumab pegol) for adults with moderate-to-severe plaque psoriasis
EC to update IP rules to benefit generic exports
The European Commission (EC) is proposing to adjust intellectual property (IP) rules to help Europe’s pharma companies tap into fast-growing global markets.
Pfizer will have to cut price of AML drug Mylotarg after NICE ruling
NICE blocks access to 65% of patients on cost grounds
Amgen’s Repatha gets EU cardio risk reduction label
But Sanofi/Regeneron could have advantage thanks to price cut and better data
FDA backs Novartis’ Gilenya in paediatric MS
First disease modifying therapy approved in paediatric MS
NICE asks EUSA pharma to drop price of neuroblastoma drug
NICE calls for price cut before possible CDF funding
